The p53 tumor suppressor protein is encoded by TP53, probably the most often mutated gene in most cancers. A review article printed in Nature Opinions Medical Oncology by Professor Klas G Wiman and colleagues on the Division of Oncology–Pathology describes how p53 may very well be used as a goal for brand spanking new most cancers therapies.
In TP53 wild-type most cancers cells, p53 is commonly inhibited by overexpression of the p53 antagonist MDM2, and brokers that disrupt p53-MDM2 binding can restore p53 exercise. In TP53-mutant most cancers cells, refolding of missense mutant p53 or translational readthrough of nonsense mutant TP53 can reactivate p53 operate.
A number of p53-targeted compounds are at the moment being examined in clinical trials in sufferers with various kinds of malignancies, however up to now no such drug has been accredited within the clinic. On this overview, Wiman and colleagues talk about the complex interactions between p53 and its microenvironment and counsel methods for enhancing scientific efficacy of p53-targeted brokers.
Amos Tuval et al, Pharmacological reactivation of p53 within the period of precision anticancer medication, Nature Opinions Medical Oncology (2023). DOI: 10.1038/s41571-023-00842-2
The position of p53 as a goal for novel most cancers therapies (2023, December 19)
retrieved 19 December 2023
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.